GHRS GH Research
- 12.810
- +0.820+6.84%
GH Research News
HC Wainwright & Co. : The GH Research (GHRS.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $40.00.
HC Wainwright & Co. : The GH Research (GHRS.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $40.00.
Buy Rating Affirmed for GH Research Amid Promising Trials and Regulatory Milestones
GH Research Is Maintained at Buy by Canaccord Genuity
GH Research Is Maintained at Buy by Canaccord Genuity
Canaccord Genuity Maintains Buy on GH Research, Raises Price Target to $31
Canaccord Genuity analyst Sumant Kulkarni maintains GH Research with a Buy and raises the price target from $30 to $31.
Analysts Offer Insights on Healthcare Companies: Veru (VERU) and GH Research (GHRS)
GH Research Q1 EPS $(0.15) Beats $(0.22) Estimate, Cash, Cash Equivalents, Other Financial Assets And Marketable Securities Were $214.0M As Of March 31
GH Research (NASDAQ:GHRS) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.22) by 31.82 percent. This is a 28.57 percent increase over losses of $(0.21)
GH Research: Cash Runway Into 2026 >GHRS
GH Research: Cash Runway Into 2026 >GHRS
GH Research 1Q Loss/Shr 15c >GHRS
GH Research 1Q Loss/Shr 15c >GHRS
GH Research Reports First Quarter 2024 Financial Results and Provides Business Updates
Phase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for expected completion of double-blind phase in Q3 2024 and of 6-month open-label extension phase in Q1 2025Phase 2a clinical
Psyched: 5-MeO-DMT For Depression, Utah Hospitals Providing Therapy, Elon Musk And Meta's Influence
Intranasal 5-MeO-DMT Clinical Trial Offers Hope For Treatment-Resistant DepressionPartners Beckley Psytech and atai Life Sciences (NASDAQ:ATAI) have jointly announced positive initial results from a P
Psyched: LSD, Psilocybin As Breakthrough Therapies, $14M Fed Grant For Ibogaine, Indiana's Research And More
FDA Grants Cybin Breakthrough Therapy Status For Major Depression Psilocybin Therapy, Company Announces Positive Clinical Data & Canadian $150M Private PlacementClinical-stage psychedelics biopharma c
Psyched: New Evidence Shows Psilocybin As Anxiety Therapy, Open-Source Learning For Therapists, Enveric's Licensing Deals And More
Psilocybin-Assisted Therapy Achieves Positive Clinical Trial Results For Treating Generalized AnxietyPsilocybin-assisted therapy has hit a milestone as clinical trial results show potential benefits f
HC Wainwright & Co. Reiterates Buy on GH Research, Maintains $40 Price Target
HC Wainwright & Co. analyst Patrick Trucchio reiterates GH Research (NASDAQ:GHRS) with a Buy and maintains $40 price target.
Buy Rating for GH Research: Promising Clinical Trials and Strategic Intellectual Property Advances
Here's Why We're Not Too Worried About GH Research's (NASDAQ:GHRS) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and mining exploration companies often lose money for years before finding success wi
GH Research Is Maintained at Market Outperform by JMP Securities
GH Research Is Maintained at Market Outperform by JMP Securities
GH Research Price Target Cut to $39.00/Share From $50.00 by JMP Securities
GH Research Price Target Cut to $39.00/Share From $50.00 by JMP Securities
JMP Securities Maintains Market Outperform on GH Research, Lowers Price Target to $39
JMP Securities analyst Jason Butler maintains GH Research (NASDAQ:GHRS) with a Market Outperform and lowers the price target from $50 to $39.
Oregon House Passes Bill to End Hard Drug Decriminalization
There are many factors in setting drug policy, which often center around the benefits or detriments to a society and its economy.
Buy Rating Justified by GH Research's Promising Clinical Trials and Strong Financial Health
Analysis
Price Target
No Data
